Compare MBWM & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBWM | VOR |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1997 | 2021 |
| Metric | MBWM | VOR |
|---|---|---|
| Price | $60.21 | $19.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $64.17 | $39.00 |
| AVG Volume (30 Days) | 99.0K | ★ 646.8K |
| Earning Date | 10-20-2026 | 10-30-2026 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 4.21 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.34 | N/A |
| Revenue Next Year | $7.39 | N/A |
| P/E Ratio | $14.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.40 | $6.50 |
| 52 Week High | $63.41 | $26.00 |
| Indicator | MBWM | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 47.33 |
| Support Level | $56.97 | $17.62 |
| Resistance Level | $62.64 | $20.11 |
| Average True Range (ATR) | 1.40 | 1.23 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 16.29 | 28.77 |
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.